lesterol levels, elevated plasma levels of apo-B,7 im paired clearance of VLDL remnants,8 and an increased prevalence of small dense low-density lipoprotein (LDL).7 A predominance of small LDL and its enhanced sus ceptibility to copper-mediated oxidative modification9 is associated with atherogenesis.10,11 Because of the report ed increased risk for premature atherosclerosis, treatment with lipid-lowering drugs is frequently indicated.12,13 In this report we described the baseline lipoprotein con centrations, LDL subtraction profiles, and LDL oxidiz ability of well-defined patients with familial combined hyperlipidemia, and compared the effectiveness of treat ment with gemfibrozil or simvastatin on these parame ters in a double-blind, placebo-controlled fashion.
W e evaluated in a double-blind, placebo-controlled, randomized trial of 4 5 well-defined patients with famil ial combined hyperlipidemia, the effect of gemfibrozil (1 ,20 0 m g/day) or simvastatin (20 m g/day) on apolipoprotein-B (apo-B)-containing lipoproteins, low-densify lipoprotein (LDL) subfraction profile, and LDL oxidiz ability. Although both drugs reduced plasma cholesterol and triglyceride concentrations, gemfibrozil reduced plasma triglycerides more effectively and simvastatin reduced plasma cholesterol more effectively. LDL cho lesterol w as reduced with simvastatin. W ith Doth drugs, total serum apo-B concentration decreased. W ith gem fibrozil, this was due to an exclusive reduction (-46% ) of very low/interm ediafe-density lipoprotein (VLDL + IDL) apo-B, whereas simvastatin decreased apo-B in both VLDL + IDL and LDL (34% and 15%, respectively). Initially, a dense LDL subfraction profile was present in all patients. The decrease in LDL cholesterol with sim vastatin was due to a decrease in all isolated LDL subfractions except LDL2; gemfibrozil increased LDL1 and LDL2 cholesterol (p = 0.001) and reduced LDL4 choles terol, resulting in a more buoyant LDL subfraction pro file compared with simvastatin. In both groups, a pre dominance of small dense LDL remained despite therapy. LDL fatty acid composition showed a shift from oleic acid to linoleic acid after gemfibrozil; arachidonic acid increased after simvastatin. Vitamin E was lower after gemfibrozil. In the measurements of LDL oxidation, only the oxidation rate was significantly reduced with simvastatin. Thus, quantitative and aualitative changes of LDL cholesterol had only a small effect on total in vitro LDL oxidizability in this population with familial combined hyperlipidemia.
(Am J Cardiol 1 9 9 5 ;7 5 :3 4 8 -3 5 3 )
F amilial combined hyperlipidemia is.a metabolically and genetically heterogeneous lipid disorder,1"3 with affected persons exhibiting elevations o f total choles terol, triglycerides, or both, at least partially caused by very-low-density lipoprotein (VLDL)-apolipoprotein-B (apo-B) overproduction.4 Its prevalence is estimated to be 0.5% to 1.0%,2 and the trait predisposes to premature cardiovascular complications. 1,5 Because of the absence of a specific metabolic parameter characteristic of famil ial combined hyperlipidemia, family studies are pivotal for diagnosis. The current diagnosis is based on the fol lowing criteria1,6: prevalence of multiple lipoprotein phenotypes in first-degree relatives, premature athero sclerosis, decreased high-dcnsity lipoprotein (HDL) cho-degree relative with significant hypercholesterolemia, hypertriglyceridemia, or both; a positive family history of premature coronary artery disease; total apo-B 100 levels >1,200 mg/dl; and age >30 years. Patients with secondary causes for dyslipidemia or with apolipoprotein phenotype E 2/2 were excluded. Low-density lipoprotein subfractionation: LDL sub fraction analysis before and after treatment was per formed by density gradient ultracentrifugation.14 For each patient at both occasions, this analysis was per formed in the same run. After ultracentrifugation, the LDL subfractions were visible as distinct bands in the middle of the tube. Up to 5 LDL subtractions could be distinguished concentrated in the following density ranges: LDL1 (1.030 to 1.033 g/ml), LDL2 (1,033 to 1.040 g/ml), LDL3 (1.040 to L045 g/ml), LDL4 (1.045 to 1.049 g/ml), and LDL5 (1.049 to 1.054 g/ml). PREVENTIVE CARDIOLOGY/EFFECT OF GEMFIBROZIL OR SIMVASTATIN IN FCH 349 ± 2.9 kg/m2, respectively). Both age and body mass index were similar in both groups. The iipid and lipopro tein levels, body mass index, and age of the 45 patients were equal compared with the initial population.
Effect of treatment on plasma lipid and lipoprotein lev els: The lipid and lipoprotein levels of the patients with familial combined hyperlipidemia before and after treat ment with gemfibrozil (n = 22) or simvastatin (n = 23) are summarized in Table I . There were no significant dif ferences in lipid concentrations between the 2 groups at Values are presented in mmol/L a s mean ± SD.
Apo-B * apolipoproteirvB; G * gemfibrozil (n -22); HDL ■ high*donsity lipoprotein; IDL « ¡ntermodiafe-donsily lipoproletn; S *» sfmvaslailn (n « 23); VLDL « very-low-densily lipoprotein. baseline. Gemfibrozil significantly affected total triglyc eride levels in plasma as well as in the VLDL + IDL fraction, whereas simvastatin induced the largest reduc tion in total plasma cholesterol. On the other hand, VLDL + IDL cholesterol was reduced with both thera pies to the same extent. The largest contribution to the reduction in total cholesterol and triglycerides was gen erated by a decrease in the VLDL + IDL fraction. LDL cholesterol only decreased with simvastatin, and even tended to increase after gemfibrozil HDL cholesterol levels increased with both drugs. Effect of treatment on apolipoprotein-B lipoproteins: A significant correlation was found between apo-B and total apo-B-related cholesterol (total cholesterol minus HDL cholesterol) (Pearsons' cor relation coefficient 0.91; p = 0.001) (Fig  ure 1) (Figure 3) , The ratio of cholesterol/triglyceride within the LDL particle increased, whereas that of Iriglyceride/apo-B decreased, probably due to a reduction in triglycerides per LDL parti cle. The ratio of cholesterol/apo-B did not change (Table II) . Simvastatin treatment reduced total LDL, but did not induce a major shift to a less dense LDL subfrac tion profile as seen with gemfibrozil. The amount of cholesterol in all LDL sub fractions, except LDL2, was significantly reduced (Figure 3) . Neither the ratio of cholesterol/triglyceride nor the ratio of cholesleroI/apo-B or triglyceride/apo-B changed significantly (Table II) Fatty acid composition and vitamin E content of low-density lipoprotein: The fat ty acid composition of each isolated LDL was determined (Table III) , For technical reasons, only the results of 14 patients treated with gemfibrozil and 15 patients with simvastatin could be analyzed. This reduction had no effect on lipid levels, apo-B levels, or the value of parameter K before and after therapy in this subset when compared with the initial 45 patients. In the gemfibrozil group, the relative amount of stearic acid (18:0) and oleic acid (18:1) decreased, whereas that of linoleic acid (18:2) increased. In the simvastatin group, .001. Values of fatty acids are presented in percentage of total Fatty acids as mean ± SD, SVilamin E in m g/g low-aensiiy lipoprotein. tfRalio of polyunsaturated fatty acids/vltamin E in |a.mol/mg, PUFA = > polyunsaturated fatty acids (fimol/mg); Vit, = vitamin; other abbreviations as in Table I .
p <0
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Total low-density lipoprotein oxidizability: Because of technical reasons, the results of only 17 patients treated with gemfibrozil versus 18 patients with simvastatin could be analyzed, This reduction had no effect on lipid and apo-B levels, or the value of parameter K before and after therapy in this subset when compared with the ini tial 45 patients. Although the lag time at the preoxidative phase tended to increase, the differences were not significant in any of the treatment groups. Oxidation rate decreased after simvastatin (p = 0.01), in contrast to gem fibrozil, Total amounts of produced conjugated dienes (malon dialdehyde reactive products) per milligram of LDL protein were similar before and after treatment in both groups.
DISCUSSION
The underlying cause of the increased tendency to ward cardiovascular diseases in patients with familial combined hyperlipidemia is probably related to increased levels of small dense LDL and other atherogenic lipopro tein remnant particles. Initially, all patients had a dense LDL subfraction pro file, both determined by cholesterol content in isolated LDL subfractions and described by a continuous vari able, parameter K. This method of approach provides the opportunity to obtain more detailed information about small alterations in the LDL subfraction profile than the often-used dichotomous classification in pattern A (light) and pattern B (heavy). 17 The increase in cho lesterol in the buoyant LDLl and LDL2 subtractions after gemfibrozil could be explained by the observed decrease in the ratio of triglycericle/protein of the LDL particle only after gemfibrozil, reflecting an overall reduction in triglycerides in the LDL particles. This tri glyceride reduction, not observed after simvastatin, is associated with more buoyant LDL subfractions.14 It is remarkable that despite the substantial reduction in plas ma triglyceride concentrations, no patient with a dense LDL subfraction profile had complete conversion to a buoyant LDL subfraction profile. Only 5 patients had conversion to an intermediate profile. These results are supported by a recent study by Hokanson et ul29 in which they proposed that in familial combined hyperlipidemia, small dense LDL and hypertriglyceridemia appear as interrelated but separate characteristics and regulated as separate processes.
In general, the observed LDL fatty acid composition in this group with familial combined hyperlipidemia was similar to that found in normal subjects.18 After both therapies, only small alterations in this composition were seen. The total amount of polyunsaturated fatty acids (linoleic and arachidonic acids), most susceptible for oxidative modification,18 did not change, On the con trary, vitamin E as the major antioxidant in LDL was reduced only with gemfibrozil. This may have implica tions for total LDL oxidizability.
Our data show only little effect on LDL oxidizabili ty after treatment, less than suspected on the basis of a more buoyant LDL subfraction profile,14 However, some explanations for this lack of change in LDL oxidizabil ity are possible: We determined LDL oxidizability in total LDL, which is the addition of maximal 5 LDL sub tractions, so small changes might be undetected. Despite treatment, these patients still had a predominance of small dense LDL particles. The ratio of cholesterol/pro tein of LDL particles con-elating with LDL oxidizabili ty30 was unaffected after both therapies. Finally, the ratio of polyunsaturated fatty acids/vitamin E increased only with gemfibrozil. This implies that the expected dimin ished susceptibility to copper-induced oxidation because of a more buoyant LDL subtraction profile14 could be offset by a reduced protection of polyunsaturated fatty acids from oxidation by vitamin E.
